Holen Sie sich die Stockscreener-App
0.7918
1.51%
0.0118
Handel nachbörslich:
.79
-0.0018
-0.23%
Schlusskurs vom Vortag:
$0.78
Offen:
$0.76
24-Stunden-Volumen:
283.29K
Relative Volume:
1.36
Marktkapitalisierung:
$8.76M
Einnahmen:
$4.03M
Nettoeinkommen (Verlust:
$24.32M
KGV:
-0.1841
EPS:
-4.3008
Netto-Cashflow:
$-45.76M
1W Leistung:
+0.23%
1M Leistung:
+21.82%
6M Leistung:
+8.55%
1J Leistung:
-56.73%
1-Tages-Spanne:
$0.73
$0.8137
1-Wochen-Bereich:
$0.7261
$0.895
52-Wochen-Spanne:
$0.5719
$3.50
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Vergleichen Sie PAVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.7918 | 8.76M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
Lucid Diagnostics secures concierge medicine contract By Investing.com - Investing.com Nigeria
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Can Lucid's New Concierge Medicine Deal Transform Its Revenue Model? - StockTitan
PAVmed regains Nasdaq compliance - MSN
PAVmed Regains Compliance with Nasdaq Listing Standards**WASHINGTON, DC—In a recent 8-K filing with the Securities and Exchange Commission, PAVmed Inc. (NASDAQ: PAVM) announced that it has successfully regained compliance with the Nasda - Defense World
PAVmed regains compliance with Nasdaq Capital Market’s CLS - Medical Buyer
PAVMPavmed Latest Stock News & Market Updates - StockTitan
PAVmed regains Nasdaq compliance with stockholders' equity By Investing.com - Investing.com Canada
PAVmed Regains Compliance With Nasdaq Listing Standards -February 18, 2025 at 10:07 am EST - Marketscreener.com
PAVmed regains Nasdaq compliance with stockholders’ equity By Investing.com - Investing.com Nigeria
PAVmed regains Nasdaq compliance with stockholders' equity - Investing.com
PAVmed regains Nasdaq compliance with equity boost By Investing.com - Investing.com South Africa
Innovative Tech Company Surges Forward: PAVmed Triumphs in Nasdaq Compliance - Smartphone Magazine
PAVmed regains Nasdaq compliance with equity boost - Investing.com India
Navigating the High Seas of Market Compliance: PAVmed’s Resilient Return - Mi Valle
PAVmed Triumphs on Nasdaq: A Medical Tech Comeback Story - Jomfruland.net
Critical Victory: PAVmed's Strategic Moves Save Nasdaq StatusFull Details Inside - StockTitan
SI-BONE (NASDAQ:SIBN) vs. Lucid Diagnostics (NASDAQ:LUCD) Head to Head Survey - Defense World
PAVmed stock touches 52-week low at $0.57 amid market challenges - MSN
Lucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review - Defense World
Lucid Diagnostics Inc (LUCD) Shares Rise Despite Market Challenges - The News Heater
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Marketscreener.com
PAVmed to Host Earnings Call - ACCESS Newswire
Lucid Diagnostics Provides Business Update and Second Quarter 20 - GuruFocus.com
PAVMed faces Nasdaq delisting over share price rule By Investing.com - Investing.com South Africa
PAVMed faces Nasdaq delisting over share price rule - Investing.com
PAVmed shareholders approve stock issuance and charter amendment - Investing.com India
PAVmed shareholders approve stock issuance and charter amendment By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - PR Newswire
Lucid Diagnostics Achieves Record-Breaking Quarter with 84% Surge in EsoGuard DNA Test Volume - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Marketscreener.com
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - GuruFocus.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
PAVmed stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
PAVmed stock plunges to 52-week low, touches $0.6 - Investing.com
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PAVmed (NASDAQ:PAVM) versus Embecta (NASDAQ:EMBC) Financial Review - Defense World
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuar - GuruFocus.com
Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PR Newswire
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):